Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_219_библиотеки_им_акад_М_И_Перельмана
.pdf
231
148. Levey, A.S. GFR decline as an end point for clinical trials in CKD: a scien-
tific workshop sponsored by the National Kidney Foundation and the US Food and Drug
Administration / Levey A.S., Inker L.A., Matsushita K. [et al.] // American Journal of
Kidney Diseases. – 2014. – Vol.64, №6. – P. 821-835.
149. Li, L. Longitudinal progression trajectory of GFR among patients with CKD
/ L. Li, B.C. Astor, J. Lewis [et al.] // American Journal of Kidney Diseases. – 2012. –
Vol.59, №4. – P. 504-512.
150. Little, M.H. Does Renal Repair Recapitulate Kidney Development? / M.H.
Little, P. Kairath. // Journal of the American Society of Nephrology. – 2017. – Vol.28. –
P. 34–46.
151. Longitudinal Estimated GFR Trajectories in Patients With and Without Type
2 Diabetes and Nephropathy / M. Weldegiorgis, D. de Zeeuw, L. Li [et al.] // American
Journal of Kidney Diseases. – 2018. – Vol.71, №1. – P. 91-101.
152. Low renal replacement therapy incidence among slowly progressing elderly
chronic kidney disease patients referred to nephrology care: an observational study
[Электронный ресурс] / U.H. Lundström, A. Gasparini, R. Bellocco [et al.] // BMC
Nephrology. – 2017. – Vol.18, №1. – P. 59. - Режим доступа: https://bmcnephrol.bio-
medcentral.com/articles/10.1186/s12882-017-0473-1
153. Management of Hypoparathyroidism: Summary Statement and Guidelines /
M.L. Brandi, J.P. Bilezikian, D. Shoback [et al.] // The Journal of Clinical Endocrinology
& Metabolism. – 2016. – Vol.101, №6. – P. 2273-2283.
154. Metabolic acidosis is associated with increased risk of adverse kidney out-
comes and mortality in patients with non-dialysis dependent chronic kidney disease: an
observational cohort study [Электронный ресурс] / N. Tangri, N.L. Reaven, S.E. Funk
[et al.] // BMC Nephrology. – 2021. – Vol.22, №1. – P. 185. - Режим доступа:
https://pubmed.ncbi.nlm.nih.gov/34011303/
155. Multicentre prospective validation of a urinary peptidome-based classifier
for the diagnosis of type 2 diabetic nephropathy / J. Siwy, J.P. Schanstra, A. Argiles [et
al.] // Nephrology Dialysis Transplantation. – 2014. – Vol.29, №8. – P. 1563-1570.
https://t.me/med1917
232
156. Multinational Assessment of Accuracy of Equations for Predicting Risk of
Kidney Failure: A Meta-analysis / N. Tangri, M.E. Grams, A.S. Levey [et al.] // JAMA
Network. – 2016. – Vol.315, №2. – P. 164-174.
157. Naber, T. Chronic Kidney Disease: Role of Diet for a Reduction in the Se-
verity of the Disease [Электронный ресурс] / T. Naber // Nutrients. – 2021. – Vol.13,
№9. – P. 3277. Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/arti-
cles/PMC8467342/
158. National kidney foundation Removing Race from Estimates of Kidney Func-
tion [Электронный ресурс]/ Режим доступа: https://www.asn-
online.org/about/press/releases/ASN_PR_20210309_Press_release_NKF_A.pdf
159. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors
and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type
2 diabetes mellitus and chronic kidney disease [Электронный ресурс] / Y. Zhang, L.
Jiang, J. Wang [et al.] // Cardiovasc Diabetol – 2022. – Vol.21, №1. – P. 232. – Режим
доступа: https://pubmed.ncbi.nlm.nih.gov/36335326/
160. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without
Race / L.A. Inker, N.D. Eneanya, J. Coresh [et al.] // The New England Journal of Medi-
cine. – 2021. – Vol.385, №19. – P. 1737-1749.
161. Nuffield Department of Population Health Renal Studies Group: .SGLT2 in-
hibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the ef-
fects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative
meta-analysis of large placebo-controlled trials. – Lancet. – 2022. – Vol.400, №10365. –
P. 1788-1801.
162. Number and frequency of albuminuria measurements in clinical trials in di-
abetic nephropathy / T.F. Kröpelin, D. de Zeeuw, D.L. Andress [et al.] // Clinical Journal
of the American Society of Nephrology. – 2015. – Vol.10, №3. – P. 410-416.
163. Optimizing Diet to Slow CKD Progression [Электронный ресурс] / P. Mo-
lina, E. Gavela, B. Vizcaíno [et al.] // Frontiers in medicine. – 2021. – Vol.8. – P. 654250.
- Режим доступа: https://pubmed.ncbi.nlm.nih.gov/34249961/
https://t.me/med1917
233
164. Patterns and predictors of kidney function decline in the last year prior to
dialysis / V. Ambrogi, N. Thilly, S. Boini [et al.] // Nephron Clinical Practice. – 2009. –
Vol.111, №2. – P. c95-c101.
165. Peer kidney care initiative 2014 report: dialysis care and outcomes in the
United States / E. Weinhandl, E. Constantini, S. Everson [et al.] // American Journal of
Kidney Diseases. – 2015. – Vol.65, №6 Suppl 1. – P. Svi, S1-140.
166. Performance of GFR Slope as a Surrogate End Point for Kidney Disease
Progression in Clinical Trials: A Statistical Simulation / T. Greene, J. Ying, E.F. Vonesh
[et al.] // Journal of the American Society of Nephrology. – 2019. – Vol.30, №9. – P.
1756-1769.
167. Peritoneal Dialysis Use and Practice Patterns: An International Survey Study
/ Y. Cho, A.K. Bello, A. Levin [et al.] // American Journal of Kidney Diseases. – 2021. –
Vol.77, №3. – P. 315-325.
168. Potassium Trajectories prior to Dialysis and Mortality following Dialysis In-
itiation in Patients with Advanced CKD / A.A. Dashputre, K. Sumida, P.K. Potukuchi [et
al.] // Nephron. – 2021. – Vol.145, №3. – P. 265-274.
169. Potential Benefit Associated With Delaying Initiation of Hemodialysis in a
Japanese Cohort / S. Higuchi, I. Nakaya, K. Yoshikawa [et al.] // Kidney International
Reports. – 2017. – Vol.2, №4. – P. 594-602.
170. Potential Surrogate Outcomes for Kidney Failure in Advanced CKD: Eval-
uation of Power and Predictive Ability in CKDopps [Электронный ресурс] / J. Zee, D.
Muenz, K.P. McCullough [et al.] // Kidney Medicine. – 2021. – Vol.4, №2. – P. 100395.
- Режим доступа: https://www.sciencedirect.com/science/arti-
cle/pii/S2590059521002533
171. Pre-dialysis acute care hospitalizations and clinical outcomes in dialysis pa-
tients [Электронный ресурс] / S. Shah, K. Meganathan, A.L. Christianson [et al.] // PLoS
One. – 2019. – Vol.14, №1. – P. e0209578. - Режим доступа:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334901/
https://t.me/med1917
234
172. Predialysis Care Trajectories of Patients With ESKD Starting Dialysis in
Emergency in France / M. Raffray, C. Vigneau, C. Couchoud, S. Bayat. // Kidney Inter-
national Reports. – 2020. – Vol.6, №1. – P. 156-167.
173. Predialysis Kidney Function and Its Rate of Decline Predict Mortality and
Hospitalizations After Starting Dialysis / M. Soohoo, E. Streja, Y. Obi [et al.] // Mayo
Clinic Proceedings. – 2018. – Vol.93, №8. – P. 1074-1085.
174. Predialysis Potassium Variability and Postdialysis Mortality in Patients With
Advanced CKD / A.A. Dashputre, P.K. Potukuchi, K. Sumida [et al.] // Kidney Interna-
tional Reports. – 2021. – Vol.6, №2. – P. 366-380.
175. Pre-ESRD Depression and Post-ESRD Mortality in Patients with Advanced
CKD Transitioning to Dialysis / M.Z. Molnar, E. Streja, K. Sumida [et al.] // Clinical
Journal of the American Society of Nephrology. – 2017. – Vol.12, №9. – P. 1428-1437.
176. Preexisting comorbidities are associated with the mortality rate as well as the
predialysis adverse events in incident dialysis patients / M.J. Lee, I. Park, H. Kim [et al.]
// Kidney Research and Clinical Practice. – 2021. – Vol.40, №3. – P. 419-431.
177. Preservation of kidney function irrelevant of total kidney volume growth rate
with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease /
S. Horie, S. Muto, H. Kawano [et al.] // Clinical and Experimental Nephrology. – 2021.
– Vol.25, №5. – P. 467-478.
178. Prevention of kidney function decline using uric acid-lowering therapy in
chronic kidney disease patients: a systematic review and network meta-analysis // S. Tsu-
kamoto, N. Okami, T. Yamada [et al.] // Clinical Rheumatology. – 2022. – Vol.41, №3.
– P. 911-919.
179. Primary kidney disease modifies the effect of comorbidities on kidney re-
placement therapy patients' survival [Электронный ресурс] / J. Helve, M. Haapio, P.H.
Groop, P. Finne. // PLoS One. – 2021. – Vol.16, №8. – P. e0256522. Режим доступа:
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0256522
180. Progression in comorbidity before hemodialysis initiation is a valuable pre-
dictor of survival in incident patients / Y.Y. Ng, Y.N. Hung, S.C. Wu [et al.] // Nephrol-
ogy Dialysis Transplantation. – 2013. – Vol.28, №4. – P. 1005-1012.
https://t.me/med1917
235
181. Progression of kidney disease in type 2 diabetes - beyond blood pressure
control: an observational study [Электронный ресурс] / D.J. Leehey, H.J. Kramer, T.M.
Daoud [et al.] // BMC Nephrology. – 2005. – Vol.6. – P. 8. Режим доступа:
https://bmcnephrol.biomedcentral.com/articles/10.1186/1471-2369-6-8
182. Progressive Decline in Estimated Glomerular Filtration Rate in Patients With
Diabetes After Moderate Loss in Kidney Function-Even Without Albuminuria / D.
Vistisen, G.S. Andersen, A. Hulman [et al.] // Diabetes Care. – 2019. – Vol.42, №10. –
P. 1886-1894.
183. Receipt of Nephrology Care and Clinical Outcomes Among Veterans With
Advanced CKD / E. Fung, T.I. Chang, G.M. Chertow [et al.] // American Journal of Kid-
ney Diseases. – 2017. – Vol.70, №5. – P. 705-714.
184. Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium.
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection:
A Meta-Analysis / H.J. Heerspink, T.F. Kröpelin, J. Hoekman, D. de Zeeuw // Journal of
the American Society of Nephrology. – 2015. – Vol.26, №8. – P. 2055-2064.
185. Relationship between history of coronary heart disease at dialysis initiation
and onset of events associated with heart disease: a propensity-matched analysis of a pro-
spective cohort study [Электронный ресурс] / D. Inaguma, S. Koide, K. Takahashi [et
al.] // BMC Nephrology. – 2017. – Vol.18, №1. – P. 79. - Режим доступа:
https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-017-0495-8
186. Removing race from the CKD-EPI equation and its impact on prognosis in a
predominantly White European population / E.L. Fu, J. Coresh, M.E. Grams [et al.] //
Nephrology Dialysis Transplantation. – 2023. – Vol.38, №1. – P. 119-128.
187. Renal disease progression in autosomal dominant polycystic kidney disease
/ E. Higashihara, S. Horie, S. Muto [et al.] // Clinical and Experimental Nephrology. –
2012. – Vol.16, №4. – P. 622-628.
188. Renal events in patients receiving neprilysin inhibitors: a systematic review
and meta-analysis / C. Vollmer Barbosa, H. Lang, A. Melk, B.M.W. Schmidt // Nephrol-
ogy Dialysis Transplantation. – 2022. – Vol.37, №12. – P. 2418-2428.
https://t.me/med1917
236
189. Renal prognoses by different target hemoglobin levels achieved by epoetin
beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to eryth-
ropoiesis-stimulating agent: a multicenter open-label randomized controlled study / K.
Tsuruya, T. Hayashi, H. Yamamoto [et al.] // Clinical and Experimental Nephrology. –
2021. – Vol.25, №5. – P. 456-466.
190. RENINE Annual Report 2018. [Электронный ресурс] / T. Hoekstra, F.W.
Dekker, K. Cransberg [et al.] // Nefrovisie. – 2018. - Режим доступа: https://www.ne-
frovisie.nl/wp-content/uploads/2019/12/20191212_RENINE-annual-report-2018.pdf.
191. Risk Factors for Prognosis in Patients With Severely Decreased GFR / M.
Evans, M.E. Grams, Y. Sang [et al.] // Kidney International Reports. – 2018. – Vol.3,
№3. – P. 625-637.
192. Risk Factors for Unplanned Dialysis Initiation: A Systematic Review of the
Literature / R. Hassan, A. Akbari, P.A. Brown [et al.] // Canadian Journal of Kidney
Health and Disease. – 2019. – Vol.6. – P.1-14.
193. Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate
Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study /
E.O. Gosmanova, K. Chen, L. Rejnmark [et al.] // Advances in Therapy. – 2021. – Vol.38,
№4. – P. 1876-1888.
194. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease
in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study // D.N.
Koye, D.J. Magliano, C.M. Reid [et al.] // American Journal of Kidney Diseases. – 2018.
– Vol.72, №5. – P. 653-661.
195. Ruggenenti, P. Progression, remission, regression of chronic renal diseases /
P. Ruggenenti, A. Schieppati, G. Remuzzi // Lancet. – 2001. – Vol.357, №9268. – P.
1601-1608.
196. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Di-
abetes / A. Doria, A.T. Galecki, C. Spino [et al.] // The New England Journal of Medicine.
– 2020. – Vol.382, №26. – P. 2493-2503.
197. Shabaka, A. Therapeutic Insights in Chronic Kidney Disease Progression
[Электронный ресурс] / A. Shabaka, C. Cases-Corona, G. Fernandez-Juarez // Frontiers
https://t.me/med1917
237
in medicine. – 2021. – Vol.8. – P. 645187. - Режим доступа: https://pub-
med.ncbi.nlm.nih.gov/33708784/
198. Shared decision-making in advanced kidney disease: a scoping review
[Электронный ресурс] / N. Engels, G.N. de Graav, P. van der Nat [et al.] // BMJ Open.
– 2022. – Vol.12, №9. – P. e055248. - Режим доступа: https://pub-
med.ncbi.nlm.nih.gov/36130746/
199. Sodium Intake and Chronic Kidney Disease [Электронный ресурс] / S.
Borrelli, M. Provenzano, I. Gagliardi [et al.] // International Journal of Molecular Sci-
ences. – 2020. – Vol.21, №13. – P. 4744. - Режим доступа: https://pub-
med.ncbi.nlm.nih.gov/32635265/
200. Starting Renal Replacement Therapy: Is It About Time? / E. Ku, C.E.
McCulloch, K.L. Johansen [et al.] // American Journal of Nephrology. – 2019. – Vol.50,
№2. – P. 144-151.
201. Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced
CKD and Risk of Adverse Outcomes: A Nationwide Study / E.L. Fu, M. Evans, C.M.
Clase [et al.] // Journal of the American Society of Nephrology. – 2021. – Vol.32, №2. –
P. 424-435.
202. Superior effect of allopurinol compared to febuxostat on the retardation of
chronic kidney disease progression [Электронный ресурс] / S. Park, J.P. Lee, D.K. Kim
[et al.] // PLoS One. – 2022. – Vol.17, №2. – P. e0264627. – Режим доступа: https://pub-
med.ncbi.nlm.nih.gov/35226683/
203. Tantisattamo, E. Association of Pre-ESRD Serum Bicarbonate with Post-
ESRD Mortality in Patients with Incident ESRD / E. Tantisattamo, V. Murray, Y. Obi [et
al.] // American Journal of Nephrology. – 2021. – Vol.52, №4. – P. 304-317.
204. Ten-year experience of an outpatient clinic for CKD-5 patients with multi-
disciplinary team and educational support / V. Terlizzi, M. Sandrini, V. Vizzardi [et al.]
// International Urology and Nephrology. – 2022. – Vol.54, №4. – P. 949-957.
https://t.me/med1917
238
205. The case for early identification and intervention of chronic kidney disease:
conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controver-
sies Conference / M.G. Shlipak, S.L. Tummalapalli, L.E. Boulware [et al.] // Kidney In-
ternational. – 2021. – Vol.99, №1. – P. 34-47.
206. The current state of chronic dialysis treatment in Japan (as of December 31,
2000) / Therapeutic Apheresis and Dialysis. – 2003. – Vol.7, №1. – P. 3-35.
207. The early decline in renal function in patients with type 1 diabetes and pro-
teinuria predicts the risk of end-stage renal disease / J. Skupien, J.H. Warram, A.M.
Smiles [et al.] // Kidney International. – 2012. – Vol.82, №5. – P. 589-597.
208. The effect of regular aerobic exercise on renal function in patients with CKD:
A systematic review and meta-analysis [Электронный ресурс]/ Q. Ma, Y. Gao, J. Lu [et
al.] // Frontiers in Physiology. – 2022. – Vol.13. – 901164 – Режим доступа:
https://www.frontiersin.org/articles/10.3389/fphys.2022.901164/full.
209. The effect of tolvaptan on autosomal dominant polycystic kidney disease pa-
tients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial / S. Muto,
H. Kawano, E. Higashihara [et al.] // Clinical and Experimental Nephrology. – 2015. –
19(5), P. 867–877.
210. The effects of dietary protein restriction and blood-pressure control on the
progression of chronic renal disease. Modification of Diet in Renal Disease Study Group
/ S. Klahr, A.S. Levey, G.J. Beck [et al.] // The New England Journal of Medicine. – 1994.
– Vol.330, №13. – P. 877-884.
211. The Impact of Iron Supplementation for Treating Anemia in Patients with
Chronic Kidney Disease: Results from Pairwise and Network Meta-Analyses of Random-
ized Controlled Trials [Электронный ресурс] / M. Adler, F. Herrera-Gómez, D. Martín-
García [et al.] // Pharmaceuticals. – 2020. – Vol.13, №5. – P. 85. – Режим доступа:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281268/
212. The Prevalence of Metabolic Acidosis in Patients with Different Stages of
Chronic Kidney Disease: Single-Centre Study Kidney / P. Kuczera, D. Ciaston-Mogilska,
B. Oslizlo [et al.] // Kidney & blood pressure research. – 2020. – Vol.45, №6. – P. 863–
872.
https://t.me/med1917
239
213. The Profile of Timing Dialysis Initiation in Patients with End-stage Renal
Disease in China: A Cohort Study / Y. Liu, L. Wang, X. Han [et al.] // Kidney and Blood
Pressure Research. – 2020. – Vol.45, №2. – P. 180-193.
214. The Validity of Drug Effects on Proteinuria, Albuminuria, Serum Creatinine,
and Estimated GFR as Surrogate End Points for ESKD: A Systematic Review / S.C.
Palmer, M. Ruospo, A. Teixeira-Pinto [et al.] // American Journal of Kidney Diseases. –
2018. – Vol.72, №6. – P. 779-789.
215. Therapeutic effects of exercise interventions for patients with chronic kidney
disease: an umbrella review of systematic reviews and meta-analyses [Электронный ре-
сурс] / F..Zhang, Y. Bai, X. Zhao [et al.] // BMJ Open. – 2022. – Vol.12, №9. – P.
e054887. – Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880113/
216. Timing of dialysis initiation to reduce mortality and cardiovascular events in
advanced chronic kidney disease: nationwide cohort study [Электронный ресурс] / E.L.
Fu, M. Evans, J.J. Carrero [et al.] // BMJ. – 2021. – Vol.375 – P. e066306. – Режим
доступа: https://pubmed.ncbi.nlm.nih.gov/34844936/
217. Tolvaptan in patients with autosomal dominant polycystic kidney disease /
V.E. Torres, A.B. Chapman, O. Devuyst [et al.] // The New England Journal of Medicine.
– 2012. – Vol.367, №25. – P. 2407-2418.
218. Transition of care from pre-dialysis prelude to renal replacement therapy: the
blueprints of emerging research in advanced chronic kidney diseas / K. Kalantar-Zadeh,
C.P. Kovesdy, E. Streja [et al.] // Nephrology Dialysis Transplantation. – 2017. – Vol.
32, Suppl. 2. – P. ii91-ii98.
219. Trends in dialysis modality choice and related patient survival in the ERA-
EDTA Registry over a 20-year period / M.W. van de Luijtgaarden, K.J. Jager, M.
Segelmark [et al.] // Nephrology Dialysis Transplantation. – 2016. – Vol.31, №1. – P.
120-128.
220. Trends in home dialysis use differ among age categories in past two decades:
A Dutch registry study [Электронный ресурс] / A.A. Bonenkamp, T. Hoekstra, M.H.
Hemmelder [et al.] European Journal of Clinical Investigation. – 2022. – Vol.52, №1. –
P. e13656. – Режим доступа: https://pubmed.ncbi.nlm.nih.gov/34293185/
https://t.me/med1917
240
221. Underbjerg, L. Long-Term Complications in Patients With Hypoparathy-
roidism Evaluated by Biochemical Findings: A Case-Control Study / L. Underbjerg, T.
Sikjaer, L. Rejnmark // Journal of Bone and Mineral Research. – 2018. – Vol.33, №5. –
P. 822-831.
222. United States Renal Data System. – 2021 USRDS Annual Data Report: Ep-
idemiology of kidney disease in the United States. Chapter 11. International Comparisons
[Электронный ресурс] / National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases, Bethesda, MD. – 2021. – Режим доступа:
https://adr.usrds.org/2021
223. Updated comorbidity assessments and outcomes in prevalent hemodialysis
patients / T.I. Chang, J. Paik, T. Greene [et al.] // Hemodialysis International. – 2010. –
Vol.14, №4. – P. 478-85.
224. Urate-lowering efficacy and renal safety of febuxostat in patients with hype-
ruricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of
observational studies [Электронный ресурс]/ H.J. Jeong, W.Y. Park, S.H. Kim [et al.] //
Seminars in Arthritis and Rheumatism. – 2022. – Vol.56. – P. 152073. - Режим доступа:
https://pubmed.ncbi.nlm.nih.gov/35914389/
225. Urgent-start dialysis in patients referred early to a nephrologist-the CKD-
REIN prospective cohort study / V. Fages, N.A. de Pinho, A. Hamroun [et al.] // Neph-
rology Dialysis Transplantation. – 2021. – Vol.36, №8. – P. 1500-1510.
226. Uribarri, J. Chronic kidney disease and kidney stones / J. Uribarri // Current
Opinion in Nephrology and Hypertension. – 2020. – Vol.29, №2. – P. 237-242.
227. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney
Disease in the United States / R. Saran, B. Robinson, K.C. Abbott [et al.] // Am J Kidney
Disease. – 2019. – Vol.73, №3 Suppl 1. – P. A7-A8.
228. US Renal Data System 2021 Annual Data Report: Epidemiology of Kidney
Disease in the United States. Volume II / K.L. Johansen, G.M. Chertow, D.T. Gilbertson
[et al.] // American Journal of Kidney Diseases. – 2022. – Vol.79, №4, Suppl 1. – P.
S178-S575.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана